

# Cristian Tomasetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8749690/publications.pdf>

Version: 2024-02-01

47  
papers

9,914  
citations

159585

30  
h-index

214800

47  
g-index

52  
all docs

52  
docs citations

52  
times ranked

14359  
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	12.6	1,872
2	Variation in cancer risk among tissues can be explained by the number of stem cell divisions. <i>Science</i> , 2015, 347, 78-81.	12.6	1,561
3	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016, 8, 346ra92.	12.4	1,036
4	Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. <i>Science</i> , 2017, 355, 1330-1334.	12.6	803
5	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1835-1848.	27.0	451
6	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207.	7.1	438
7	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. <i>JAMA Oncology</i> , 2019, 5, 1710.	7.1	383
8	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. <i>Science</i> , 2020, 369, .	12.6	351
9	Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1999-2004.	7.1	348
10	Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2261-2272.	27.0	337
11	Only three driver gene mutations are required for the development of lung and colorectal cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 118-123.	7.1	325
12	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	12.1	234
13	Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 9846-9851.	7.1	178
14	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	178
15	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1118.	7.1	152
16	A multimodality test to guide the management of patients with a pancreatic cyst. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	129
17	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. <i>ELife</i> , 2018, 7, .	6.0	118
18	Role of symmetric and asymmetric division of stem cells in developing drug resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16766-16771.	7.1	90

#	ARTICLE	IF	CITATIONS
19	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	8.4	88
20	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. <i>Journal of Pathology</i> , 2019, 248, 41-50.	4.5	84
21	Prognostic significance of postsurgery circulating tumor <scp>DNA</scp> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	5.1	77
22	Cell division rates decrease with age, providing a potential explanation for the age-dependent deceleration in cancer incidence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20482-20488.	7.1	63
23	Cancer risk: Role of environmentâ€™Response. <i>Science</i> , 2015, 347, 729-731.	12.6	59
24	An elementary approach to modeling drug resistance in cancer. <i>Mathematical Biosciences and Engineering</i> , 2010, 7, 905-918.	1.9	52
25	Assessing aneuploidy with repetitive element sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4858-4863.	7.1	50
26	Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. <i>Modern Pathology</i> , 2019, 32, 1544-1550.	5.5	45
27	Revisiting the tumorigenesis timeline with a data-driven generative model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 857-864.	7.1	44
28	Role of stem-cell divisions in cancer risk. <i>Nature</i> , 2017, 548, E13-E14.	27.8	42
29	Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. <i>Nature Biotechnology</i> , 2021, 39, 1220-1227.	17.5	40
30	Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 733-742.	8.1	31
31	Mutated clones are the new normal. <i>Science</i> , 2019, 364, 938-939.	12.6	28
32	The (not so) immortal strand hypothesis. <i>Stem Cell Research</i> , 2015, 14, 238-241.	0.7	22
33	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3516-3516.	1.6	19
34	The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. <i>International Journal of Cancer</i> , 2019, 145, 540-547.	5.1	15
35	On the slope of the regression between stem cell divisions and cancer risk, and the lack of correlation between stem cell divisions and environmental factors-associated cancer risk. <i>PLoS ONE</i> , 2017, 12, e0175535.	2.5	12
36	Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer. <i>ELife</i> , 2021, 10, .	6.0	12

#	ARTICLE	IF	CITATIONS
37	On the Probability of Random Genetic Mutations for Various Types of Tumor Growth. Bulletin of Mathematical Biology, 2012, 74, 1379-1395.	1.9	11
38	An argument for mechanism-based statistical inference in cancer. Human Genetics, 2015, 134, 479-495.	3.8	9
39	A new hypothesis: imatinib affects leukemic stem cells in the same way it affects all other leukemic cells. Blood Cancer Journal, 2011, 1, e19-e19.	6.2	7
40	Evaluating the impact of multicancer early detection testing on health and economic outcomes: Toward a decision modeling strategy. Cancer, 2022, 128, 892-908.	4.1	7
41	Drug Resistance. Advances in Experimental Medicine and Biology, 2014, 844, 303-316.	1.6	6
42	Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial.. Journal of Clinical Oncology, 2022, 40, LBA100-LBA100.	1.6	5
43	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, e16206-e16206.	1.6	4
44	Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors. F1000Research, 2013, 2, 152.	1.6	2
45	1124 A MULTI-MODALITY TEST TO GUIDE THE MANAGEMENT OF PATIENTS WITH PANCREATIC CYSTS. Gastrointestinal Endoscopy, 2019, 89, AB143-AB144.	1.0	1
46	Stochastic Modelling of Multiple Random Genetic Mutations Under the Cancer Stem Cell Hypothesis. Mathematical Population Studies, 2012, 19, 200-213.	2.2	0
47	The Average Baseline BCR-ABL Levels Are Significantly Higher in Patients with Resistance to Dasatinib As First-Line Treatment for Early Chronic Phase Chronic Myeloid Leukemia. Blood, 2012, 120, 4436-4436.	1.4	0